| Applied methods of cost-effectiveness analysis in healthcare AM Gray, PM Clarke, JL Wolstenholme, S Wordsworth OUP Oxford, 2010 | 835 | 2010 |
| A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) PM Clarke, AM Gray, A Briggs, AJ Farmer, P Fenn, RJ Stevens, ... Diabetologia 47, 1747-1759, 2004 | 772 | 2004 |
| Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) P Clarke, A Gray, R Holman Medical Decision Making 22 (4), 340-349, 2002 | 607 | 2002 |
| UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom … AJ Hayes, J Leal, AM Gray, RR Holman, PM Clarke Diabetologia 56, 1925-1933, 2013 | 468 | 2013 |
| The Lancet Commission on diabetes: using data to transform diabetes care and patient lives JCN Chan, LL Lim, NJ Wareham, JE Shaw, TJ Orchard, P Zhang, ... The Lancet 396 (10267), 2019-2082, 2020 | 466 | 2020 |
| Missing.... presumed at random: cost‐analysis of incomplete data A Briggs, T Clark, J Wolstenholme, P Clarke Health economics 12 (5), 377-392, 2003 | 427 | 2003 |
| Effects of allopurinol on the progression of chronic kidney disease SV Badve, EM Pascoe, A Tiku, N Boudville, FG Brown, A Cass, P Clarke, ... New England Journal of Medicine 382 (26), 2504-2513, 2020 | 361 | 2020 |
| The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) P Clarke, A Gray, R Legood, A Briggs, R Holman Diabetic Medicine 20 (6), 442-450, 2003 | 348 | 2003 |
| Estimating the association between SF-12 responses and EQ-5D utility values by response mapping AM Gray, O Rivero-Arias, PM Clarke Medical Decision Making 26 (1), 18-29, 2006 | 257 | 2006 |
| Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial J Simon, A Gray, P Clarke, A Wade, A Neil, A Farmer bmj 336 (7654), 1177-1180, 2008 | 246 | 2008 |
| Applied methods of cost-benefit analysis in health care E McIntosh Oxford University Press, 2010 | 237 | 2010 |
| Forgetting to remember or remembering to forget: a study of the recall period length in health care survey questions G Kjellsson, P Clarke, UG Gerdtham Journal of health economics 35, 34-46, 2014 | 234 | 2014 |
| Optimal recall length in survey design PM Clarke, DG Fiebig, UG Gerdtham Journal of health economics 27 (5), 1275-1284, 2008 | 221 | 2008 |
| Horizontal inequities in Australia's mixed public/private health care system E Van Doorslaer, P Clarke, E Savage, J Hall Health Policy 86 (1), 97-108, 2008 | 198 | 2008 |
| On the measurement of relative and absolute income-related health inequality PM Clarke, UG Gerdtham, M Johannesson, K Bingefors, L Smith Social science & medicine 55 (11), 1923-1928, 2002 | 183 | 2002 |
| Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) PM Clarke, AM Gray, A Briggs, RJ Stevens, DR Matthews, RR Holman, ... Diabetologia 48, 868-877, 2005 | 176 | 2005 |
| Development of life-expectancy tables for people with type 2 diabetes J Leal, AM Gray, PM Clarke European heart journal 30 (7), 834-839, 2009 | 175 | 2009 |
| Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis PM Clarke, P Glasziou, A Patel, J Chalmers, M Woodward, SB Harrap, ... PLoS medicine 7 (2), e1000236, 2010 | 173 | 2010 |
| Funding grant proposals for scientific research: retrospective analysis of scores by members of grant review panel N Graves, AG Barnett, P Clarke Bmj 343, 2011 | 161 | 2011 |
| Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013 X Hua, N Carvalho, M Tew, ES Huang, WH Herman, P Clarke Jama 315 (13), 1400-1402, 2016 | 159 | 2016 |
